1-溴-2-甲氧基-丙烷 | 23465-33-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-溴-2-甲氧基-丙烷
• 英文名称: 1-bromo-2-methoxypropane
• 英文别名: 1-Brom-2-methoxy-propan
• CAS: 23465-33-0
• 化学式: C₄H₉BrO
• mdl: MFCD20621723
• 分子量: 153.019
• InChiKey: ULHBRIULGNSYDP-UHFFFAOYSA-N

物化性质

• 沸点：
  65 °C(Press: 30 Torr)
• 密度：
  1.336±0.06 g/cm3(Predicted)
• 保留指数：
  754

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  6
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-溴-2-甲氧基-丙烷 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-甲氧基丙胺盐酸盐
  参考文献：
  名称：

  Gagnaire,D., Bulletin de la Societe Chimique de France, 1960, p. 1813 - 1826

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-二甲氧基丙烷 在 5-溴化铌 98 、 水 作用下， 以 二氯甲烷 、 chloroform-d8 为溶剂， 反应 48.0h， 生成 1-溴-2-甲氧基-丙烷
  参考文献：
  名称：

  Further insights into the chemistry of niobium and tantalum pentahalides with 1,2-dialkoxyalkanes: Synthesis of bromo- and iodoalkoxides, spectroscopic and computational studies

  摘要：

  The room temperature reactions of a series of 1,2-dialkoxyalkanes ROCH2CH(R')OR" with MX5 (M = Nb, Ta; X = Br, I) in 1:1 ratio result in single C-O bond cleavage and high-yield formation of the halo-alkoxides MBr4[K-2-OCH2CH(R')OR"] or [Nbl(4){K-1-OCH2CH(R')OR")](2), and equimolar amounts of the corresponding alkyl halides RX. The reaction of NbBr5 with 1,2-climethoxyethane, dme, proceeds with preliminary formation of the ionic species (NbBr4(K-2-dme)(K-1-dme)][NbBr6], 3b, which has been identified by solution NMR at low temperature and conductivity analyses. The gas-phase structure of 3b has been optimized by DFT calculations, confirming that the dme ligands adopt bidentate and monodentate coordination, respectively. Although the formation of NbOBr3(dme), 4b, 1,4-dioxane and MeBr from NbBr5/dme (ratio 1:2) is an exoergonic process (calculated Delta G(r)(degrees) = -115.96 kcal mol(-1)), it is inhibited at room temperature. High temperature conditions enhance the production of 1,4-dioxane at the expense of selectivity. The dinuclear species NbOBr3(dme)NbBr5 (Nb-O-Nb), 5b, (X-ray) has been isolated in modest yield as byproduct of the room temperature reaction of NbBr5 with dme. In general, the 1:2 molar reactions of NbX5 (X = Br. I) with ROCH2CH(R')OR" occur with the exclusion of nearly one equivalent of organic reactant. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2011.03.005

文献信息

• HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180065981A1

  公开（公告）日：2018-03-08

  The present application relates to novel thieno[2,3-d]pyrimidine-2,4-dione (“thienouracil”) derivatives bearing a particular type of (azaheterocyclyl)methyl substituent, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of pulmonary and cardiovascular disorders and of cancer.

  本申请涉及具有特定类型的(氮杂杂环基)甲基取代基的新型噻吩并[2,3-d]嘧啶-2,4-二酮（“噻吩尿嘧啶”）衍生物，以及其制备方法，单独或组合用于治疗和/或预防疾病，以及用于生产用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防肺部和心血管疾病以及癌症的用途。
• [EN] PHENOXYTRIAZOLES<br/>[FR] PHÉNOXYTRIAZOLES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018087018A1

  公开（公告）日：2018-05-17

  The present invention relates to a compound of formula I, HetAr is a five or six membered heteroaryl group, selected from wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy or lower alkyl substituted by halogen, and may be the same or different, if two R1 occur; R2 is lower alkyl or a mono- or polydeutered derivative thereof, lower alkyl substituted by halogen or lower alkoxy, lower alkenyl unsubstituted or substituted by halogen, cycloalkyl or CH2-cycloalkyl unsubstituted or substituted by halogen, heterocycloalkyl or CH2-heterocycloalkyl unsubstituted or substituted by lower alkyl; R3 is halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy substituted by halogen or S(0)2-lower alkyl; n is 1, 2 or 3; if n is >1, then R3 may be the same or different; or to a pharmaceutically active acid addition salt thereof, to a racemic mixture or to its corresponding enantiomer and/or an optical isomer and/or stereoisomer thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.

  本发明涉及一种具有式I的化合物，其中HetAr是选择自的五元或六元杂环芳基，其中R1是氢、卤素、较低烷基、较低烷氧基或被卤素取代的较低烷基，且可以相同或不同，如果存在两个R1；R2是较低烷基或其单重或多重氘代衍生物，被卤素取代的较低烷基或较低烷氧基，未取代或被卤素取代的较低烯基，未取代或被卤素取代的环烷基或CH2-环烷基，未取代或被卤素取代的杂环烷基或 -杂环烷基，被较低烷基取代的卤素、较低烷基、被卤素取代的较低烷基、被卤素取代的较低烷氧基或S(0)2-较低烷基；n为1、2或3；如果n>1，则R3可以相同或不同；或其药学活性酸盐，或其外消旋混合物，或其对映体和/或光学异构体和/或立体异构体。这些化合物可用于治疗阿尔茨海默病、脑淀粉样血管病、遗传性脑出血伴淀粉样变性、荷兰型（HCHWA-D）、多梗死性痴呆、拳击性痴呆或唐氏综合征。
• Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis
  作者：Ivo Monkovic、David Willner、Michael A. Adam、Myron Brown、R. R. Crenshaw、Carl E. Fuller、Peter F. Juby、George M. Luke、John A. Matiskella、Thomas A. Montzka

  DOI：10.1021/jm00403a011

  日期：1988.8

  A series of new substituted benzamides has been synthesized and evaluated for dopamine antagonist activity and for antagonism of cisplatin-induced emesis in the dog and in the ferret. It was found that modification of the 2-methoxy substituent of metoclopramide was detrimental to dopaminergic D2 antagonism but not necessarily to antagonism of cisplatin-induced emesis. A number of analogues having a

  合成了一系列新的取代的苯甲酰胺，并对狗和雪貂中多巴胺拮抗剂的活性以及顺铂诱导的呕吐的拮抗作用进行了评估。发现对甲氧氯普胺的2-甲氧基取代基的修饰不利于多巴胺能D2拮抗作用，但不一定不利于顺铂诱导的呕吐。具有β-酮基，β-羟基，β-甲氧基，β-亚氨基或β-不饱和烷氧基取代基而不是甲氧基的许多类似物已显示出与甲氧氯普胺同等或更好的呕吐保护作用。同时，在体外（[3H] spiperone结合）和体内试验（大鼠僵直症，阿扑吗啡对大鼠的定型作用的拮抗作用以及阿扑吗啡对呕吐的拮抗作用）中，发现这些化合物都没有多巴胺能D2拮抗作用。狗）。
• Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
  申请人：Sanofi-Aventis

  公开号：US08076336B2

  公开（公告）日：2011-12-13

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  本发明涉及公式I的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、Q1、Q2和Q3分别如下定义。公式I的化合物具有抗血栓活性，特别是抑制蛋白酶活化受体1（PAR1）。本发明还涉及制备公式I化合物的方法以及将其用作药物的用途。
• TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
  申请人：HEINELT Uwe

  公开号：US20120010203A1

  公开（公告）日：2012-01-12

  The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.

  本发明涉及一种新型化合物I，其中R1，R2，R3，R4，R5，R6，R7，R8，Q1，Q2和Q3分别如下所定义。公式I的化合物具有抗血栓活性，并特别抑制蛋白酶活化受体1（PAR1）。本发明还涉及一种制备公式I的化合物的方法，并将其用作药物的用途。